Dravet Syndrome When Pharmaceutical-Grade Cannabidiol Has Not Achieved Seizure Control

This protocol covers the management of Dravet syndrome in patients where pharmaceutical-grade cannabidiol — deployed as first-, second-, or third-line treatment — has failed to prevent prolonged convulsive seizures or status epilepticus.

Previous treatment — failure condition Pharmaceutical-grade cannabidiol was the prior antiseizure therapy. It did not achieve the key clinical goal of avoiding prolonged convulsive seizures and status epilepticus, triggering escalation to this next-line protocol.

Next-line approach (partial overview) The protocol involves a specific antiseizure agent and, where indicated, a structured dietary intervention — with the type of dietary approach determined by the patient's age. Full eligibility criteria, sequencing, and options are detailed in the complete protocol.

Clinical goal Avoidance of prolonged convulsive seizures and status epilepticus. In Dravet syndrome, the accepted standard centres on preventing the most dangerous seizure events rather than complete seizure freedom.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/epi.17274

Dietary therapy should be considered after failure of three or four ASMs (Strong; Table 4).

The classical ketogenic diet was recommended for children 6 years and younger (Moderate) and the modified Atkins diet for teens and adults (Strong).

There was modest consensus among caregivers, but no consensus among physicians to support topiramate as first-, second-, or third-line therapy.

In DS, it is appropriate to accept infrequent, brief convulsive seizures with the main goal focused on avoiding prolonged convulsive seizures and status epilepticus (physicians: n = 19, 79%; caregivers: n = 9, 56%).

View source ↗